癌症
医学
中性粒细胞与淋巴细胞比率
内科学
白蛋白
淋巴细胞
胃肠病学
胃食管交界处
免疫学
腺癌
作者
ITARU HASHIMOTO,Kazuki Kano,SHIZUΝE ONUMA,HIDEAKI SUEMATSU,Shinsuke Nagasawa,KYOHEI KANEMATSU,Kyoko Furusawa,Tomomi Hamaguchi,Mamoru Watanabe,Kei Hayashi,Mitsuhiro Furuta,Yasuhiro Inokuchi,Nozomu Machida,TORU AOYAMA,Takanobu Yamada,Yasushi Rino,Takashi Ogata,Takashi Oshima
出处
期刊:Anticancer Research
[International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
日期:2023-03-27
卷期号:43 (4): 1689-1697
被引量:4
标识
DOI:10.21873/anticanres.16321
摘要
Trifluridine/tipiracil (FTD/TPI) is an anticancer-agent that is administered as third-line or later chemotherapy for metastatic gastric/gastroesophageal junction cancer (mGC/GEJC). Although inflammatory and nutritional statuses have attracted attention as prognostic factors for patients with mGC/GEJC in this therapy, their usefulness has not been fully clarified. Thus, this study investigated the clinical significance of prognostic nutritional index (PNI), neutrophil/lymphocyte ratio (NLR), and NLR/serum albumin (Alb) ratio in patients administered FTD/TPI.This retrospective study included 64 patients who underwent FTD/TPI treatment for mGC/GEJC at Kanagawa Cancer Center, Kanagawa, Japan, between October 2019 and June 2022. Patients were divided into high and low PNI, NLR, and NLR/Alb groups according to their pretreatment blood data. This study evaluated the associations between the inflammatory and nutritional indexes and survivals.Overall survival (OS) and progression-free survival (PFS) of patients with low PNI were significantly poorer than those with high PNI. However, low PNI was not an independent prognostic factor for OS and PFS. There was no significant association between NLR and OS or PFS. In contrast, the OS of patients with high NLR/Alb was significantly poorer than those with high PNI and low NLR/Alb. Furthermore, multivariate analysis showed that high NLR/Alb was an independent prognostic factor for OS.The NLR/Alb may be a useful prognostic factor in patients with mGC/GEJC being administered FTD/TPI as third-line or later chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI